A historic day – for the first time ever, a magnetomotive ultrasound was applied to human tissue

Yesterday was a historic day for NanoEcho. To our knowledge, this is the first time ever that the magnetomotive ultrasound method has been applied to human tissue. This was carried out on operated cancer tissue using NanoEcho's first generation portable system at Sahlgrenska University Hospital in Gothenburg. Our system is designed to map, with high precision, the spread of cancer to the lymph nodes, an important marker of how far the cancer has progressed, even before surgery. Our clinical study is now underway at Sahlgrenska University Hospital.

It was a very educational day, and we appreciate the professional leadership of Senior Consultant and Professor, Eva Angene, and her team's engaging approach. Everything has gone according to plan, and we have succeeded in identifying nanoparticles in the human tissue. As such, we have achieved our goal with the first patient. We now look forward to continuing the clinical study on operated tissue, and gathering knowledge and receiving guidance in readiness for the design and system development of the next system, adapted for commercialisation, says Linda Persson, CEO of NanoEcho. 

One year ago, we submitted our joint ethics application for this clinical study. Due to the burden on healthcare from Covid, the start was delayed. It is exciting to finally be up and running, and I look forward to following the development of the study, says Professor and Senior Consultant, Eva Angenete, who is leading the study at Sahlgrenska University Hospital. 

This press release was published in Swedish in 18 June 2021.

Basic patent granted in Japan

The basic patent for NanoEcho's method has now been granted in Japan. We have also received positive feedback on the same patent in Europe from the European Patent Office, which has announced that it intends to grant the patent. The same patent is also under review in Canada and the US, where the process is also progressing according to plan.

The patent protects the unique combination of placing an ultrasonic transducer together with one or more magnets on the same device, as such the basic patent protects the performance of a handheld probe. The magnets create an alternating magnetic field which, together with the ultrasonic transducer, is used to locate iron oxide-based nanoparticles. 

We work actively with our patent portfolio and continuously evaluate how we can best strengthen and expand our patent portfolio as our product development progresses. This is to ensure the use of strategically and technically important innovations. The Japanese market accounts for approximately 8.5 per cent of the global rectal cancer market, says Linda Persson, CEO of NanoEcho. 

This press release was published in Swedish in 1 July 2021. 

First patient recruited in clinical trial on surgically removed tissue

NanoEcho has been given the go-ahead to begin clinical trials on surgically removed rectal cancer tissue at Sahlgrenska University Hospital in Gothenburg and at Skåne University Hospital in Malmö. The first patient has now been recruited at Sahlgrenska University Hospital. NanoEcho is developing a new medical imaging technique for the diagnosis of rectal cancer. The ambition is to contribute to a more reliable mapping of cancer spread to nearby lymph nodes, which is an important marker of how far along the cancer is.

The first patient has now been recruited at Sahlgrenska University Hospital. On June 17 the clinical trail, on surgically removed rectal cancer tissue, will start using the company's first-generation portable system, under the condition that nothing unforeseen happens. The recruitment procedure is ongoing at Skåne University Hospital in Malmö as well. The studies will compare results from NanoEcho's diagnostic method with other imaging modalities such as magnetic resonance imaging (MRI) and pathology. Patient recruitment will be ongoing at both university hospitals and the studies will last for one to two years from their respective start dates.

The results of these clinical development studies will be used to evaluate the effectiveness of our existing system and guide the design of our next system for commercialization. Together, these two studies will provide us with a comprehensive analysis of the system's performance, as both patients with different positions of the tumor in the rectum and patients with different stages of cancer are included," says NanoEcho CEO Linda Persson. 

Eva Angenete, Professor of Surgery and Senior Consultant at Sahlgrenska University Hospital, is leading the study in Gothenburg, which will include about 20 patients:

In the study, we will ensure that the system works to easily diagnose lymph node proliferation. This could be a very interesting and good development towards a simpler and cheaper diagnostic tool. 

Henrik Thorlacius, Professor of Surgery at Lund University and Senior Consultant at Skåne University Hospital in Malmö, is leading the study in Malmö, which will involve about 40 patients:

Patients will undergo routine standard surgery. Once the cancer is removed from the patient, we will take the surgically removed specimen and examine it with NanoEcho's instrument and then compare the result with the final microscopic examination by the pathologist.

 

Ethics application approved for preclinical study at Skåne University Hospital

NanoEcho will conduct a preclinical study led by Henrik Thorlacius, Professor of Surgery at Lund University and Chief Physician at Skåne University Hospital in Malmö, in which NanoEcho’s new instrument for detection of lymph nodes with cancer spread will be evaluated. The study will be carried out at Skåne University Hospital in Malmö and will include about 40 patients that will undergo he usual routine standard surgery. Once the cancer is removed from the patient, the surgical preparate will be examined with NanoEcho’s instrument. The result will then be compared with the pathologist’s final microscopic examination.

– My hope for the clinical trial is that we will be able to validate that NanoEcho's instrument is able to provide high-precision identification of lymph nodes containing cancer cells. If so, we will proceed with further clinical trials, where NanoEcho’s instrument will be evaluated in patients prior to surgery, says Henrik Thorlacius.

– I am very pleased to announce that our joint ethics application has been approved. This entails that we will implement our preclinical trials at two of the major university hospitals in Sweden, in Gothenburg and Skåne. We are currently discussing a start date for the study, and we hope to be able to commence with this study as well during the second quarter. The start date may of course be affected by the prevailing COVID-19 restrictions. I look forward to get started with the study and look with expectation to the outcome, says Linda Persson, NanoEcho's CEO.

Link to a short video where Henrik Thorlacius tells more about the study.

NanoEcho publishes investor letter

Read more about CEO Linda Persson and CTO Magnus Santesson as they tell more about their work to establish a strong company culture with a focus on delivery.

“It is essential that we ourselves are as driven as our staff, and that we maintain the same commitment that we want to see from them,” says Linda and Magnus.

You will also meet Professor and Chief Physician Henrik Thorlacius, senior medical advisor to NanoEcho, as he details how NanoEcho’s method may help rectal cancer patients in the future. 

Nanoecho.se använder cookies för att förbättra hemsidans funktionalitet för dig som användare. Är det okej?